POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT)

Saved in:

Bibliographic Details
Published in:	Hematological oncology Vol. 37; no. S2; pp. 226 - 227
Main Authors:	Thieblemont, C, Leonard, J, Trneny, M, Izutsu, K, Fowler, N, Hong, X, Zhang, H, Offner, F, Scheliga, A, Nowakowski, G, Pinto, A, F Re, Fogliatto, L, Scheinberg, P, Flinn, I, Moreira, C, Czuczman, M, Kalambakas, S, Fustier, P, C Wu, Gribben, J
Format:	Journal Article
Language:	English
Published:	Chichester Wiley Subscription Services, Inc 01-06-2019
Subjects:	Immunotherapy Lymphoma Monoclonal antibodies Rituximab Targeted cancer therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	1099-1069
DOI:	10.1002/hon.41_2630